Device Regulatory Pathways: 510(k), PMA, and De Novo

Introduction

The FDA regulatory architecture for drugs and devices differs fundamentally. Drugs go through a single pathway (NDA or BLA) with variations in speed (expedited pathways). Devices have three entirely distinct pathways that differ in evidence requirements, timeline, cost, and the competitive moat they create. Understanding which pathway a device uses is critical for healthcare bankers because it directly impacts development cost projections, time-to-revenue assumptions, and the durability of competitive position in valuation models.

The FDA classifies medical devices into three risk-based classes, and each class maps to a primary regulatory pathway:

Predicate Device

A legally marketed device to which a new device is compared in a 510(k) submission. The predicate must have the same intended use and either the same technological characteristics or different characteristics that do not raise new questions of safety and effectiveness. The predicate chain can extend back decades; a device cleared in 2025 may reference a predicate from 1995, which itself referenced a predicate from 1985. Critics argue this chain allows substantially different devices to reach market without independent safety testing, while industry argues the system enables iterative innovation.

The 510(k) pathway is the workhorse of device regulation. Approximately 85% of new device submissions to the FDA use this pathway. The manufacturer demonstrates that the new device is "substantially equivalent" to a predicate device already legally marketed in the US.

What it requires: A comparison to one or more predicate devices showing the same intended use and similar technological characteristics. Bench testing data is almost always required. Clinical data is required in only about 10-15% of 510(k) submissions (typically when the device has different technological characteristics that could affect safety or effectiveness).

Timeline and cost: Average FDA review time is approximately 100-120 days (3-4 months) from submission. Total development and regulatory cost for a typical 510(k) device is $20,000-$100,000, orders of magnitude less than a PMA. The user fee is approximately $13,000 for small companies and $22,000 for large companies (2025 rates).

The PMA pathway is the most rigorous regulatory pathway for medical devices, required for Class III (highest-risk) devices. PMA requires the manufacturer to demonstrate reasonable assurance of safety and effectiveness through valid scientific evidence, nearly always including clinical trial data.

What it requires: Preclinical testing (bench and animal studies), one or more clinical trials (often randomized controlled trials with hundreds to thousands of patients), manufacturing quality system documentation, and detailed labeling. The submission itself can be thousands of pages.

Timeline and cost: Average FDA review time is approximately 180 days (6 months) from filing, but the total timeline from development initiation to approval is typically 3-7 years when including clinical trials. Total development cost for a PMA device is $50-100 million or more, driven primarily by clinical trial costs.

PMA Supplement vs. Original PMA

After initial PMA approval, modifications to the device require PMA Supplements rather than new PMA applications. Supplements come in several types: Panel Track (significant changes, ~180 days), 180-Day (moderate changes), Real-Time (minor changes, ~30 days), and Special (manufacturing changes). The supplement system allows incremental device improvements without repeating the full PMA process. Understanding which modifications trigger which supplement type is important for modeling the timeline and cost of device iteration post-approval.

Competitive moat: PMA devices enjoy the strongest regulatory competitive protection. A competitor cannot simply reference the PMA-approved device as a predicate; they must submit their own PMA application with independent clinical evidence. This creates a 3-7 year regulatory head start that is nearly impossible to shortcut, functioning similarly to regulatory exclusivity in pharma.

The De Novo pathway was created for novel, low-to-moderate risk devices that have no predicate (and therefore cannot use the 510(k) pathway) but do not warrant the burden of a full PMA. Before De Novo existed, these devices defaulted to Class III/PMA, creating an excessive regulatory burden for devices that were genuinely lower risk but simply novel.

What it requires: Performance and safety data (which may include clinical data, though often less extensive than PMA), a proposed classification with special controls, and risk analysis. De Novo submissions are typically less burdensome than PMA but more rigorous than 510(k).

Timeline and cost: Average FDA review time is approximately 150-200 days (5-7 months), though total review times have historically been longer due to additional information requests. Development cost is intermediate, typically $200,000-$2 million depending on clinical data requirements.

The regulatory pathway directly impacts several inputs in a MedTech financial model:

Revenue timing. A 510(k) device can be generating revenue within 12-18 months of development start. A PMA device may take 5-7 years. This timeline difference dramatically affects the NPV of a product's projected cash flows and the amount of capital needed before revenue generation.

Development cost. The difference between $50,000 (510(k)) and $50+ million (PMA) in development cost affects the company's capital needs, dilution for early-stage companies, and return-on-investment calculations for each product.

Competitive durability. PMA-approved products can maintain pricing power for longer because the regulatory barrier deters competitors. 510(k)-cleared products face competitive entry sooner, creating ASP pressure that must be built into long-term revenue projections.

The next article covers Software as a Medical Device, where the regulatory framework is evolving rapidly to address AI/ML-enabled devices.